Global Infectious Diseases Partnering Analysis 2012-2018: Updated Deal Trends, Players and Financials Report - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Global Infectious Diseases Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

Global Infectious Diseases Partnering 2012 to 2018 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

Trends in Infectious Diseases dealmaking in the biopharma industry since 2012 Analysis of Infectious Diseases deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Infectious Diseases deal contract documents Comprehensive access to over 3500 Infectious Diseases deal records The leading Infectious Diseases deals by value since 2012 Most active Infectious Diseases dealmakers since 2012

Available deals and contracts are listed by:

Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

2.1. Introduction

2.2. Infectious Diseases partnering over the years

2.3. Infectious Diseases partnering by deal type

2.4. Infectious Diseases partnering by industry sector

2.5. Infectious Diseases partnering by stage of development

2.6. Infectious Diseases partnering by technology type

2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Infectious Diseases partnering

3.1. Introduction

3.2. Disclosed financials terms for Infectious Diseases partnering

3.3. Infectious Diseases partnering headline values

3.4. Infectious Diseases deal upfront payments

3.5. Infectious Diseases deal milestone payments

3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers

4.1. Introduction

4.2. Most active in Infectious Diseases partnering

4.3. List of most active dealmakers in Infectious Diseases

4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory

5.1. Introduction

5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Infectious Diseases therapeutic target


Appendix 1 - Directory of Infectious Diseases deals by company A-Z 2012 to 2018

Appendix 2 - Directory of Infectious Diseases deals by deal type 2012 to 2018

Appendix 3 - Directory of Infectious Diseases deals by stage of development 2012 to 2018

Appendix 4 - Directory of Infectious Diseases deals by technology type 2012 to 2018

For more information about this report visit https://www.researchandmarkets.com/research/kpksg5/global_infectious?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005899/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 11:39 AM/DISC: 09/25/2018 11:39 AM


Update hourly